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Abstract. Erythema nodosum leprosum (ENL) or type 2 lepra reactions complicate lepromatous leprosy and bor-
derline lepromatous leprosy. We report an 11-year retrospective case record analysis of 481 outpatients with borderline
lepromatous and lepromatous leprosy at the Dhoolpet Leprosy Research Center in Hyderabad, India.. The overall
prevalence of ENL was 24%, 49.4% among cases of lepromatous leprosy (LL) and 9% among cases of borderline
lepromatous (BL) leprosy. Logistic regression analysis identified LL (odds ratio [OR]  8.4, 95% confidence interval
[CI]  4.6–15.4, P < 0.001) and BL with a bacterial index  4+ (OR  5.2, 95% CI  2.1–12.9, P  0.001) as major
risk factors. The average patient with ENL was male, 34.7 years of age, and had multiple episodes of ENL (mean 3.1)
over an 18.5-month period. Three types of ENL were identified: single acute ENL, multiple acute ENL (repeated
discrete episodes), and chronic ENL (continuous episodes). Acute single ENL is rare, accounting for only 8% of cases.
Chronic ENL accounted for 62.5% of the cohort. Chronic ENL was of longer duration and more severe. An age  35
years was a risk factor for developing chronic ENL. Patients with chronic ENL were more compliant with multi-drug
therapy, especially during the first six doses of multi-drug therapy. Distinguishing these different types of ENL would
be useful for patient management and developing improved treatment of these debilitating reactions. Improved strat-
egies for treatment and management of these reactions need to be developed.
INTRODUCTION
Erythema nodosum leprosum (ENL) or type 2 reactions
are serious, difficult to manage, immune-mediated complica-
tions of lepromatous leprosy (LL) and borderline leproma-
tous (BL) leprosy. Patients with ENL become acutely sick
with fever, malaise, and crops of painful erythematous nod-
ules.1 Inflammation often affects other systems causing iritis,
neuritis, myositis, lymphadenitis, arthritis, dactylitis, and or-
chitis. The underlying pathology is of antigen-antibody im-
mune complex deposition,2 but there is also evidence of T cell
and macrophage dysregulation with overproduction of the
cytokine tumor necrosis factor .3 Thirty years ago during the
dapsone monotherapy era, the prevalence of ENL was ap-
proximately 50% and 30% among LL and BL patients re-
spectively.4 These prevalences have decreased with the wide-
spread implementation of multi-drug therapy for multibacil-
lary (MB) leprosy recommended by the World Health
Organization (WHO-MB-MDT) partly because of earlier di-
agnosis and treatment and partly because clofazimine, one of
the core anti-bacterial drugs, also has an anti-inflammatory
effect.5 Contemporary estimates of the frequency of ENL
among lepromatous patients range from 25% of new multi-
bacillary patients in Brazil,6 to 26% of lepromatous patient in
northeastern Thailand,7 to 5% in Ethiopia.8
ENL has a relapsing and remitting course that may last for
several years. Levy and others found that ENL produces
greater disability than the underlying lepromatous leprosy
and was the commonest reason for admission to the hospital.9
Treatment requires immunosuppression. Steroids are often
used as the first-line treatment but patients may require treat-
ment over several years. Thalidomide is highly effective in
treating the acute inflammation and also in maintaining long
term immunosuppression with few side effects.10 Although
ENL is widely recognized to have a long time course, there
are no data of the time course of ENL for individual patients.
We have classified ENL into three types, acute ENL, com-
prising a single episode; acute recurrent ENL, comprising
multiple discrete episodes; and chronic ENL, with continuous
episodes. These types of ENL could have different risk fac-
tors and require different therapeutic intervention. If patients
who were likely to have only single, widely spaced episodes of
ENL could be identified, they could be safely treated with
short courses of steroids with no risk of steroid dependency or
adverse effects. Defining these different types could be im-
portant in designing therapeutic interventions and health care
planning.
There is little data on risk factors for ENL. One study from
Nepal of 118 patients identified LL (odds ratio [OR] 2.88)
and skin infiltration (OR  2.71) as the most important risk
factors.1 An age greater than 40 years was a protective factor
(OR  0.69). In that study, the average number of ENL
episodes per patient was two, using three months as the time
interval to define a new ENL episode.1
The present study was conducted in Hyderabad, Andhra
Pradesh, India from January 1990 to December 2000, an 11-
year period when MDT was used as standard therapy, to
determine the prevalence of ENL in BL and LL patients;
identify risk factors for developing ENL; describe the number
of episodes and duration of ENL in this cohort; classify ENL
into acute and chronic forms; and identify risk factors for the
different types of ENL.
MATERIALS AND METHODS
The study was a retrospective review conducted at the
Dhoolpet Leprosy Research Center/Lepra India Blue Peter
Research Center (DLRC/BPRC) in Hyderabad, Andhra
Pradesh, India. This is a leprosy referral center situated in
Hyderabad, India. This center is funded by the United King-
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dom Medical Research Council through Lepra India. Leprosy
patients are self-referred and physicians are referred. It does
not have an associated leprosy control program. We exam-
ined the hospital records of all treated and untreated BL
leprosy patients and LL patients registered between January
1990 and December 2000. The study was reviewed and ap-
proved by the Blue Peter Research Committee.
Data were collected from the patients’ first consultation
through their monthly reviews while receiving MDT to
completion of antibacterial treatment from the patient record
cards. These data included year of birth, sex, Ridley-Jopling
classification at diagnosis, bacterial index (BI), total number
of doses of MB-MDT taken, total length of time taking MB-
MDT, and episodes of ENL.
For patients with ENL, we also collected the date of leprosy
diagnosis at the research center, year of leprosy onset, the
date of starting and ending each episode of ENL, severity,
number of MB-MDT doses taken, total amount of predniso-
lone given, highest dose of prednisolone given at each ENL
episode, and total amount of clofazimine given. To describe
the ENL episodes, the data was collected from monthly re-
views and then summarized by ENL episodes. During this
period, MB patients were only released from treatment after
completing 24 monthly doses of MB-MDT. Patients receiving
non–MB-MDT treatments had to complete at least two years
of treatment and have a BI < 2 to be released from treatment.
Case definitions. Borderline lepromatous leprosy and lep-
romatous leprosy. These Ridley-Jopling classifications were
determined clinically by the morphology of the skin lesions
and pattern of nerve involvement, together with a BI, and
were often supported by histologic examination of a skin bi-
opsy specimen.
Case definition of ENL. The criterion for a diagnosis of
ENL was the appearance of tender skin nodules. This could
be accompanied by fever and other systemic symptoms such
as joint pain, bone tenderness, neuritis, edema, malaise, an-
orexia, and/or lymphadenopathy. Patients with systemic
symptoms but without typical ENL skin nodules were ex-
cluded from the study.
Treatment of ENL. All mild to severe episodes of ENL at
the DLRC/BPRC were treated initially with a high dose of
prednisolone that was tapered by 5 mg per week. Patients
with neuritis were treated with a monthly fixed steroid regi-
men that was reduced by 5 mg each month. Tapering could
last five months if the patient was treated with an initial dose
of 25–40 mg of steroids.
Timing of ENL episodes. The end of an ENL episode was
dated to the day when steroid tapering ended and if the pa-
tient did not have ENL and was not receiving prednisolone at
the next review. An ENL episode was considered new if the
interval between episodes was more than 15 days from not
receiving steroids.
ENL definitions. The following case definitions were used.
Single acute ENL was one ENL episode lasting less than six
months with a steady decrease in steroid tapering, no recur-
rence of ENL when receiving prednisolone, and no increase
in severity requiring an increased steroid dose. These patients
also had no history of previous ENL. The criteria of six
months had to be used as a cut-off because steroid tapering
may take that long in the presence of neuritis. Acute multiple
ENL was more than one ENL episode with the same charac-
teristics as acute single ENL. Chronic ENL was an episode
lasting for more than six months. This could include single
and multiple episodes. Patients with only one ENL episode
with a borderline duration (5–6 months) were considered as
having chronic ENL if during the steroid tapering phase they
developed fresh ENL when receiving prednisolone and the
steroid dose had to be increased. Mixed acute and chronic
ENL, which was observed in those patients with both acute
and chronic ENL, was an episode lasting more than six
months, but also some acute episodes (usually less than three
months). These patients were added to the chronic ENL
group for the comparison analysis.
Severity of ENL. The following scoring system was devel-
oped and applied to the cases. Very mild ENL was non-
specific signs and symptoms, one or two non-tender skin ENL
nodules, low-grade fever or no fever, and undefined aches
and pains. Mild ENL was few, mild, tender, skin nodules
accompanied by low-grade fever, malaise, and systemic symp-
toms, e.g., joint pain. No ENL on steroids was the absence of
signs and symptoms of ENL during steroid intake. Moderate
ENL was mild ENL plus neuritis or more than three systemic
symptoms. Severe ENL was illness with toxicity, multiple skin
nodules, high-grade fever, dehydration, and other organ in-
volvement such as orchitis, iritis, or severe neuritis. Intrac-
table ENL was an episode of mild or moderate ENL while
receiving  10 mg of steroids. The following scores were
assigned: 0  no ENL; 1  very mild ENL; 2  mild ENL;
3  no ENL on steroid therapy; 4  mild ENL on steroid
therapy; 5  moderate ENL; 6  severe ENL; and 7 
intractable ENL.
Highest severity during intake of the first 12 MB-MDT
doses. Severity of ENL was categorized at each follow-up and
the highest severity during the first 12 MB-MDT doses was
recorded. This variable is an average of the highest severity
among groups.
Treatment for ENL. Very mild ENL episodes were usually
treated with aspirin or a non-steroidal anti-inflammatory drug
or chloroquine for 10–15 days. All episodes of mild to severe
ENL were treated with steroids and the dose was determined
by the severity. Some patients with chronic ENL also received
extra clofazimine.
Compliance. A coefficient of compliance was derived by
dividing the number of monthly MDT doses taken by the
number of months. Thus, the WHO recommended definition
of compliance for an MB patient is taking 12 doses of MB-
MDT taken over an 18-month period, giving a coefficient of
0.67. Patients who took their 24 doses of MB-MDT over more
than a 36-month period were defined as irregular. Compli-
ance was only applied to patients with at least 12 months of
follow-up data.
Duration of ENL. Total duration of ENL was calculated by
adding all ENL episodes and ENL-free intervals between
them for each patient. The MB-MDT duration was defined as
the time period from the date of the first dose of MB-MDT
until the date of the last dose.
Patients who had had previous ENL treated elsewhere
were not counted for the timing of the first onset of ENL. The
MB-MDT doses taken by patients before treatment at the
DLRC/BPRC were added to the amount taken in these cen-
ters. Other treatments included dapsone monotherapy; pauci-
bacillary-MDT; rifampicin, ofloxacin and minocycline; dap-
sone plus clofazimine; and clofazimine given by other hospi-
tals, private practitioners, or village programs.
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Statistical analysis. Categorical data were tested for asso-
ciation using the chi-square test. The geometric mean was
used when the data were skewed. Differences in means were
tested using the Z-test. Both comparative analyses were done
using STATA version 7 (Stata Corporation, College Station,
TX) for multivariate logistic regression analysis. The expo-
sure variables chosen for the multivariate analysis were based
on the association found between them and the outcome of
interest using the likelihood ratio test.
The data were used in three different analyses. The first
analysis was a comparative analysis between cases with and
without ENL to identify risk factors for developing ENL.
Here the outcome definition was the presence of ENL, and
subjects were divided into cases and controls. The second
analysis was a descriptive comparison of the different types of
ENL. The group data for each type of ENL was discussed and
a typical detailed case history for each type was given with
graphs showing the relationship between ENL severity,
monthly MB-MDT taken, highest weekly prednisolone dose
given, monthly cumulative prednisolone dose given, monthly
clofazimine given, and BI. The third analysis was a compari-
son of cases with chronic versus acute multiple ENL to iden-
tify risk factors for each type. The ENL cases were subdivided
into those with acute multiple ENL (cases) and chronic ENL
(controls). The outcome was developing acute multiple ENL.
The acute ENL category also included cases with recurrent
acute ENL. The chronic ENL category combined cases whose
ENL episodes that lasted for more than six months and those
that had chronic and acute episodes. Only patients with at
least one year of follow-up were included in this ENL com-
parison analysis.
RESULTS
Patient data. Four hundred eighty-one patients with LL
and BL leprosy were treated at the DLRC/BPRC between
January 1990 and December 2000 (LL, n  180, 37.4%; BL
leprosy, n  301, 62.6%). One hundred sixteen developed
ENL. The overall prevalence of ENL in this cohort was
24.1%, of whom 89 (76.7%) were LL patients and 27 (23.3%)
were BL leprosy patients. The ENL prevalence among LL
patients was 49.4% (89 of 180) and the ENL prevalence
among BL leprosy patients was only 9.0% (27 of 301). Figure
1 shows the percentage of LL and BL leprosy cases develop-
ing ENL grouped by a BI  4 or < 4.
Risk factors for developing ENL. The ENL cases and BL
leprosy/LL controls without ENL were compared to deter-
mine the risk factors for developing ENL (Table 1). Both
groups had a similar age range at the time of leprosy diagno-
sis. (33.1 versus 31.7 years). Cases who developed ENL had
significantly higher BIs at diagnosis (3.5 versus 2.0; P < 0.001)
and the onset of ENL than the non-ENL controls. The cases
with ENL also had taken significantly more MDT (17.9 versus
12.0 months; P < 0.001) and for a longer time (24.7 versus 19.8
months). The two groups were similar in terms of compliance.
The average compliance coefficient was 0.8 (95% confidence
FIGURE 1. Leprosy type, bacterial index (BI), and erythema nodosum leprosum (ENL) at the Blue Peter Research Centre/Dhoolpet Leprosy
Research Center, Hyderabad, India, 1990–2000. BL  borderline lepromatous leprosy; LL  lepromatous leprosy.
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interval [CI]  0.7–0.8), which is equivalent to 24 monthly
doses taken in 31.6 months or 12 monthly doses taken in 15.8
months. Table 2 summarizes the number and percentages of
ENL cases and controls and the crude and adjusted odd ratios
for all variables used in this analysis.
Logistic regression analysis. All variables were analyzed
with logistic regression as main explanatory variables. When
unadjusted ORs were obtained, the factors associated with
ENL were having LL, a BI  4, and taking more than 24
monthly doses of MB-MDT. All had a P value  0.001.
A multivariate logistic regression model was constructed
for each associated factor and all were adjusted by each other.
We confirmed that having LL is a significant risk factor for
developing ENL; LL patients were 8.4 times more likely to
have ENL than BL leprosy patients (95% CI 4.6–15.4, P <
0.001). The Ridley-Jopling classification and BI at diagnosis
were important determinants for ENL; LL patients with a BI
> 4 were 19 times more likely to have ENL than BL leprosy
patients with a BI < 4. The LL patients with a BI  4 were
only 3.2 times more likely to have ENL than BL patients with
a BI  4. By comparison, BL patients with a BI  4 are 5.2
times more likely to have ENL than BL patients with a BI <
4. The LL patients with a BI  4 are as likely as LL patients
with a BI < 4 to have ENL. The ENL cases were 2.6 times
more likely to have taken  24 doses of MB-MDT than non-
cases (95% CI  1.1–6.3, P  0.025).
Different types of ENL and four typical cases Acute single
ENL. Group data. Only five patients had an acute single
episode of ENL. Four had received some treatment else-
where before diagnosis at the DLRC/BPRC. All were men
with an average age at diagnosis of 38.3 years (range  23–
60). Three had BL leprosy and two had LL. The average BI
at diagnosis was 2.1 (range 0–4.66). Two of them had a BI
TABLE 2
Crude and adjusted odd ratios (ORs) comparing ENL cases versus non-cases at the DLRC/BPRC, Hyderabad, Andhra Pradesh, India,
1990–2000*
Variables No ENL ENL cases
Unadjusted
OR 95% CI Wald P
Adjusted OR
ignoring
interaction 95% CI Irtest P
Adjusted
OR 95% CI Irtest P
Age at diagnosis, years
< 35 176/359 (49.0) 49/93 (52.7) 1.0
 35 183/359 (51.0) 44/93 (47.3) 0.9 0.5–1.4 0.529
Sex
Male 262/362 (72.4) 69/93 (74.2) 1.0
Female 100/362 (27.6) 24/93 (25.8) 0.9 0.5–1.5 0.726
Classification
BL (interaction:
LL if BI < 4) 275/365 (75.3) 25/93 (22.6) 1.0 1.0 19.0 8.0–45.2 < 0.001
LL (interaction:
LL if BI  4) 90/365 (24.7) 72/93 (77.4) 10.5 6.1–18.0 < 0.001 8.4 4.6–15.4 < 0.001 3.2 1.5–7.0 0.002
Bacterial index at
diagnosis
< 4 (interaction:
BI  4 if BL) 248/351 (70.7) 35/93 (37.6) 1.0 1.0 5.2 2.1–12.9 0.001
 4 (interaction:
BI  4 if LL) 103/351 (29.3) 58/93 (62.4) 4.0 2.5–6.4 < 0.001 1.6 0.9–2.8 0.105 0.8 0.4–1.6 0.499
Total MB-MDT taken
at DLRC/BPRC,
days
1–23 205/356 (57.6) 28/93 (30.1) 1.0 1.0 NA
 24 151/356 (42.4) 65/93 (69.9) 2.3 1.4–3.7 0.001 2.6 1.1–6.3 0.025
Total time taking MB-
MDT at DLRC/
BPRC, days
1–23 215/351 (61.3) 45/91 (49.5) 1.0 1.0
 24 136/351 (38.8) 46/91 (50.5) 1.6 1.0–2.6 0.042 0.9 0.4–2.0 0.767
WHO compliance
Regular 244/333 (73.3) 70/90 (77.8) 1.0
Irregular 89/333 (26.7) 20/90 (22.2) 0.8 0.5–1.4 0.387
* BL  borderline lepromatous; LL  lepromatous leprosy; WHO  World Health Organization. For definitions of other abbreviations, see Table 1. Bold P values indicate statistical
significance.
TABLE 1
Comparison of means between ENL cases and non-cases at the
DLRC/BPRC, Hyderabad, Andhra Pradesh, India, 1990–2000*
No ENL cases ENL cases
Z-test
PMean (95% CI) Mean (95% CI)
Age, years 33.1 (31.6–34.7) 31.7 (29.2–34.5) 0.220
BI at leprosy Dx 2.0 (1.8–2.2) 3.5 (3.2–3.8) < 0.001
Bi at ENL onset 1.3 (1.0–1.5) 2.7 (2.3–3.1) < 0.001
MB-MDT 12.0 (11.1–12.9) 17.9 (16.3–19.5) < 0.001
Time taking
MB-MDT
(months) 19.8 (17.6–21.9) 24.7 (21.5–27.9) 0.031
Compliance 0.8 (0.7–0.8) 0.8 (0.7–0.8) 0.850
* ENL  erythema nodosum leprosum; DLRC/BPRC  Dhoolpet Leprosy Research
Centre/Blue Peter Research Centre; CI confidence interval; BI bacterial index; Dx
MB-MDT multi-drug therapy for multibacillary leprosy. Bold P values indicate statistical
significance.
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of 0. One had been treated with dapsone monotherapy for
five years and the other received only two monthly MB-MDT
doses. The average MB-MDT taken was 20.8 monthly doses
(range  17–24). Three of them had ENL at diagnosis. The
other two developed ENL between three and six months after
starting treatment at the BPRC/DLRC. The average highest
prednisolone dose given to these patients per month was 22
mg, and the total amount of prednisolone given for this single
episode ranged from 210 mg to 2.310 mg.
Typical acute single ENL case. Figure 2 shows the only
case with no previous leprosy treatment. This 50-year-old
man had a BI at diagnosis of 4.66 and came to the clinic with
ENL. His ENL was mild and he was treated with predniso-
lone, 15 mg for one week, and tapered by 5 mg per week. The
episode lasted 21 days.
Acute Multiple ENL. Group data. Twenty-six patients had
acute multiple ENL. Twenty-three had LL and three had BL
leprosy. The mean age of this group was 32 years (range 
8–55). The average BI at diagnosis was 3.5 and 2.7, respectively,
at the time of the first ENL episode. The average time from
starting treatment at the DLRC to onset of ENL was seven
months (range 0–24). The average number of ENL episodes
was 3.4 (range  2–10). The average time from first ENL epi-
sode to the last one was 12 months. The average total MB-
MDT monthly doses taken was 18 (minimum 6, maximum
 26). The average coefficient of compliance was 0.6, which
was equivalent to 12 MB-MDT doses in 20 months or 24/40.
Case history. Figure 3 shows data of a patient with acute
recurrent or multiple ENL. This 45-year-old man had LL and
a BI at diagnosis of 4.3. The first leprosy symptoms were
noticed by the patient three years earlier. He developed ENL
15 days after starting MB-MDT. This was a mild ENL with
neuritis, classified here as moderate ENL. The highest daily
prednisolone dose given to this patient was 25 mg in the first
episode.
He had nine more episodes of acute ENL of similar severity
over the next 30 months. He took 25 monthly MB-MDT over
a 40-month period, but very irregularly in the last half of
treatment. After a self-break from treatment, he had only 2
ENL episodes separated from each other by a period of 23
weeks. He had a BI of 0.5 three years after diagnosis and 0.0
two years later. He was followed-up for six years and has had
no additional ENL episodes.
Chronic ENL. Group data. There were 55 patients (13
with BL leprosy and 36 with LL) with chronic ENL; 18 had
only chronic ENL episodes and 37 had mixed episodes of
acute and chronic ENL. The average age at diagnosis in this
group was 31.9 years (range  12–62). The mean BI was 3.7
at diagnosis and 3.1 at onset of ENL. These patients had an
average of 2.3 years of reported symptomatic leprosy before
treatment started. The average onset of ENL was 2.3 months
after starting MB-MDT at the DLRC/BPRC (range  0–6).
The average number of ENL episodes was 2.8 (minimum 
1, maximum  10). The mean total length of ENL duration
was 18 months and that of MB-MDT was 20 doses (range 
0–25 MB-MDT doses; the minimum value of 0 is for a patient
who had 24 MB-MDT doses at another facility and was re-
ferred for management of ENL). The compliance coefficient
was 0.8, which is equivalent to 12 doses in 15 months or 24/30.
Case history. Figure 4 shows the clinical data for a 30-year-
old untreated man with BL with LL. At diagnosis, he had
neuritis and was given MB-MDT plus extra clofazimine and
prednisolone for one month. Two months later, he developed
neuritis again accompanied by dactylitis, arthralgia, bone ten-
derness, and edema of both feet. He had no skin nodules or
fever. He was started on prednisolone 20 mg, but one week
later it had to be increased to 30 mg because of the severity of
the symptoms. It was tapered monthly over a four-month
period and ENL reappeared when he reached a prednisolone
dose 10 mg. Six and a half months later, he developed fever,
skin nodules, arthritis, neuritis, and bone tenderness after
stopping prednisolone for four days. He then had continuous
ENL with periods off prednisolone of less than 15 days. When
prednisolone was stopped, the patient developed severe ENL
that became intractable with symptoms when he was taking
prednisolone that included neuritis, red and painful eyes,
FIGURE 2. Clinical indices in a typical case of acute, single erythema nodosum leprosum (ENL) at the Blue Peter Research Centre/Dhoolpet
Leprosy Research Center, Hyderabad, India, 1990–2000. MB-MDT  multi-drug therapy for multibacillary leprosy.
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bone tenderness, and joint pains. The patient had been ad-
vised to decrease his prednisolone dose, but he bought more
steroids and was probably taking even higher doses for some
unquantified periods. The ENL was uncontrolled when his
prednisolone dose was less than 15 mg/day. When he com-
pleted MDT, clofazimine was then given alone at a higher
dose and the steroids were then tapered successfully. This
patient took at least 15,580 mg of prednisolone over a 31-
month period, but no side effects were reported. This patient
took 25 monthly MB-MDT doses in 28 months (coefficient
0.89). His BI was 4.33 at diagnosis, 2.83 one year later, and 4.0
two years later, and then decreased to 1.0.
Figure 5 shows data of a patient with chronic ENL and a
mixed pattern of acute and chronic episodes. She was a 25-
year-old woman with BL leprosy. She was diagnosed in 1994,
but defaulted until 1997, when she observed with mild ENL
and not received any MDT. Her BI was 3.0 in 1997, and it
increased to 4.25 one and a half year later, but decreased
rapidly to 0.6 the following year. She was initially treated with
prednisolone, 25 mg, for one month, which was tapered to 20
mg for another month because of accompanying nerve dam-
age. She then re-presented with ENL and was receiving 20 mg
of prednisolone. She then required intermittent high doses of
prednisolone over the first eight months of her treatment.
The steroid tapering was particularly difficult in this patient
because she received relatively high doses and failed to attend
her follow-up reviews.
The patient started regularly attending her follow-up re-
views after the eighth MB-MDT dose and her ENL then be-
came continuous. She received additional clofazimine, 200
mg/day, from her 12th to 24th dose of MB-MDT and had only
one additional episode of severe ENL. She had mild ENL
FIGURE 4. Clinical indices in a typical case of chronic erythema nodosum leprosum (ENL) at the Blue Peter Research Centre/Dhoolpet
Leprosy Research Center, Hyderabad, India, 1990–2000. MB-MDTmulti-drug therapy for multibacillary leprosy; S & S signs and symptoms;
BI  bacterial index..
FIGURE 3. Clinical indices in a typical case of acute, multiple erythema nodosum leprosum (ENL) at the Blue Peter Research Centre/Dhoolpet
Leprosy Research Center, Hyderabad, India, 1990–2000. MB-MDT  multi-drug therapy for multibacillary leprosy.
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that required 5 or 10 mg of prednisolone a day until complet-
ing her chemotherapy. Her ENL can be summarized as rang-
ing from intractable to no ENL while receiving steroids; after
receiving extra clofazimine she had milder ENL.
Comparison between chronic and acute multiple ENL.
Acute multiple and chronic forms of ENL are compared in
Table 3. Of the original cohort of 116 patients, 28 were ex-
cluded because they had too short a follow-up and could not
be categorized. The remaining 88 patients were grouped into
33 (37.5%) with acute multiple ENL and 55 (62.5%) with
chronic ENL. The group with acute ENL included 7 patients
with acute single ENL and 26 with acute multiple ENL. The
group with chronic ENL included 18 patients with chronic
ENL and 37 patients with mixed ENL. The two groups were
similar for age, sex, Ridley-Jopling classification, BI at diag-
nosis, previous anti-leprosy treatment, total number of ENL
episodes, and amount of MB-MDT (all with P > 0.05, for
means and categorical data).
The mean BI at diagnosis was 3.5 (95% CI 3.3–3.9, range
 0–6). Both groups had symptoms of leprosy for three years
before diagnosis (95% CI  2.1–3.6). The ENL in both
groups started soon (3.7 months) after starting treatment. The
average number of ENL episodes was 3.1 (95% CI 2.7–3.5,
range  1–10). The average MB-MDT taken was 18.5
monthly doses in both groups.
The patients with chronic ENL had a longer average dura-
tion of disease (16.9 months) than patients with acute multiple
ENL (10.7 months) (P  0.049). Thirty-one (67.4%) of 46
patients had chronic ENL for more than 12 months and 18
(54.6%) of 33 patients had acute multiple ENL for less than
TABLE 3
Comparison of means for chronic and acute multiple ENL at the DLRC/BPRC, Hyderabad, Andhra Pradesh, India, 1990–2000*
All ENL cases Cases with chronic ENL Cases with acute ENL
t-test
Pn Mean (95% CI) n Mean (95% CI) n Mean (95% CI)
ENL onset (months) 43 3.7 (2.2–5.2) 26 2.8 (1.4–4.1) 17 5.1 (1.8–8.4) 0.128
Total ENL episodes 88 3.2 (2.7–3.5) 55 3.0 (2.5–3.5) 33 3.3 (2.5–3.1) 0.481
Total ENL duration (months) 79 18.5 (15.4–21.5) 46 21.0 (17.3–24.7) 33 14.9 (9.7–20.1) 0.049
First ENL episode duration (days) 72 154 (112–196) 46 207.5 (148–267) 26 59 (38–80) 0.004
Second ENL episode duration (days) 60 108 (66–149) 35 148 (80–216) 25 51 (34–68) 0.012
Total duration of MB-MDT intake (months) 86 25.6 (22.8–28.6) 53 22.5 (20.0–25.0) 33 30.5 (24.8–36.3) 0.004
ENL duration/MB-MDT duration 39 0.7 (0.6–0.8) 22 0.8 (0.6–0.9) 17 0.6 (0.4–0.7) 0.085
Compliance coefficient 86 0.8 (0.7–0.8) 53 0.9 (0.8–0.9) 33 0.7 (0.6–0.8) 0.001
Compliance during first 6 MB-MDT 82 0.8 (0.8–0.9) 50 0.9 (0.8–0.9) 32 0.7 (0.6–0.8) 0.013
Compliance during second 6 MB-MDT 69 0.9 (0.8–0.9) 46 0.9 (0.9–1.0) 23 0.8 (0.7–0.9) 0.060
Compliance during after first 12 MB-MDT 56 0.8 (0.8–0.9) 36 0.9 (0.8–0.9) 20 0.8 (0.6–0.9) 0.087
ENL severity 65 2.4 (1.1–2.5) 39 3.2 (2.7–3.6) 26 1.3 (0.8–1.8) < 0.001
First ENL episode severity 88 3.0 (2.6–3.4) 55 3.3 (2.8–3.7) 33 2.6 (1.9–3.3) 0.116
Overall severity related to MB-MDT intake 65 2.4 (2.0–2.8) 39 3.2 (2.7–3.6) 26 1.3 (0.8–1.8) < 0.001
Severity during first 6 MB-MDT doses intake 81 2.6 (2.3–2.9) 49 3.2 (2.9–3.6) 32 1.7 (1.2–2.1) < 0.001
Severity during second 6 MB-MDT doses intake 72 2.5 (2.1–2.9) 46 3.1 (2.7–3.5) 26 1.4 (1.0–1.9) < 0.001
Severity after first 12 MB-MDT doses intake 71 2.6 (2.3–2.9) 45 3.2 (2.9–3.5) 26 1.5 (1.1–1.9) < 0.001
Severity after completion of MB-MDT 45 0.9 (0.5–1.3) 30 1.2 (0.7–1.8) 15 0.1 (0.0–0.3) 0.006
Highest severity during first 12 MB-MDT doses 86 5.4 (5.1–5.8) 53 5.9 (5.7–6.2) 33 4.6 (4.0–5.2) < 0.001
Severity before clofazimine intake 40 3.9 (3.5–4.3) 31 4.0 (3.6–4.4) 9 3.4 (2.4–4.5) 0.226
Severity during clofazimine intake 40 2.8 (2.4–3.2) 31 3.1 (2.7–3.5) 9 1.7 (1.0–2.5) 0.002
Severity after clofazimine intake 28 0.9 (0.4–1.4) 20 1.0 (0.3–1.8) 8 0.6 (0.0–1.2) 0.410
Prednisolone per month 74 337 (264–411) 43 421 (308–533) 31 222 (155–289) 0.007
* For definition of abbreviations, see Table 1. Bold P values indicate statistical significance.
FIGURE 5. Clinical indices in a typical case of mixed acute and chronic erythema nodosum leprosum (ENL) at the Blue Peter Research
Centre/Dhoolpet Leprosy Research Center, Hyderabad, India, 1990–2000. MB- MDT  multi-drug therapy for multibacillary leprosy.
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12 months. Thirty (65%) of 46 patients with chronic ENL had
an overall disease duration that lasted  75% of the total
MB-MDT intake duration and 24 (73%) of 33 patients with
acute multiple ENL had an overall disease duration that
lasted < 75% of the total MB-MDT intake duration.
Overall compliance for cases with chronic ENL was more
regular than for patients with acute ENL (P  0.001). Com-
pliance during first six MB-MDT doses was more regular
among case with chronic ENL than in cases with acute ENL,
but was similar in both groups during the rest of the MB-
MDT intake period (Figure 6).
When we compared patients with chronic ENL with those
with acute multiple ENL, we found that those with chronic
ENL had a higher average prednisolone monthly dose (421
mg/month) than those with acute multiple ENL (222 mg/
month) (P  0.007), a higher severity score (2.5 versus 1.8)
(P  0.072) for the duration of ENL, and a disease that was
more difficult to control. Forty-five percent with chronic dis-
ease continued to have ENL (more than mild) while taking
prednisolone compared with 23% in those with acute multiple
ENL. Twenty-one (54%) of 39 patients with chronic ENL had
an overall mean severity  3 during MB-MDT intake com-
pared with one patient with acute multiple ENL.
Table 3 shows the sequential severity scores for patients
with chronic ENL and those with and acute multiple ENL.
The severity score was highest at the start of ENL in both
groups (3.2 versus 1.3) and decreased more slowly in patients
with chronic ENL. The severity scores were significantly
higher at each time point in patients with chronic ENL (P <
0.001) (Figure 7). Thirty-three (67%) of 49 patients with
chronic ENL had a severity score  3 during the first 6 MB-
MDT doses compared with 2 (6%) of 32 patients with acute
multiple ENL. These figures were 65% (30 of 46) and 8% (2
of 26), respectively, for the second six months of MDT and
46% (18 of 39) and 4% (1 of 24) for the second 12 months of
MDT.
We used this data set to assess the effectiveness of clo-
fazimine in controlling ENL. Forty (45.5%) patients (9 with
acute multiple ENL and 31 with chronic ENL) received extra
clofazimine for  4 months. The mean severity score before
additional clofazimine was 4.0 for patients with chronic ENL
and 3.4 for patients with acute ENL (P  0.226). This de-
creased to 3.1 and 1.7 (P  0.002), respectively, during clo-
fazimine intake and to 1.0 and 0.6 (P  0.410), respectively,
after clofazimine intake, indicating that the drug probably
ameliorates ENL. However, clofazimine was used late in
treatment, with 64.5% of patients with chronic ENL starting
their extra clofazimine after the sixth MB-MDT dose com-
pared with 89% of the patients with acute multiple ENL who
started it during the first six months of chemotherapy.
Patients with acute and chronic ENL were compared by
logistic regression analysis. Table 4 summarizes the number
and percentages of patients with chronic and acute multiple
ENL and the crude and adjusted ORs by the analysis vari-
ables. All variables were checked with logistic regression as
main explanatory variables. When unadjusted ORs were ob-
tained, the factors associated with chronic ENL were being
less than 35 years of age (P 0.031), more severe ENL (P
0.037), ENL lasting  75% that of the MB-MDT duration
(P 0.001), developing severe ENL during first 12 MB-MDT
doses (P < 0.001), regular MB-MDT compliance during first
six doses (P < 0.001), regular MB-MDT compliance from the
13th dose to release from treatment (P 0.014), overall regu-
lar compliance (P < 0.001), higher severity during the first six
MB-MDT doses, the second six MB-MDT doses, and the rest
of the MB-MDT doses (P < 0.001 for all), and higher severity
during additional intake of clofazimine.
Logistic regression was done for each associated factor.
When the effect of these variables was adjusted by the other
risk factors and other cofounders, an association was found
between chronic ENL and overall ENL severity and severity
during first 6 MB-MDT doses. Being  35 years of age and
irregular MB-MDT compliance (overall and during first six
doses) protected against development of chronic ENL. (All <
0.008, except overall severity P < 0.05).
Patients with acute multiple ENL were more likely to be
FIGURE 6. Compliance with multi-drug therapy for multibacillary leprosy (MB-MDT) in patients with acute and chronic erythema nodosum
leprosum (ENL) types. The dotted line indicates the World Health Organization compliance coefficient of 0.67.
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receiving irregular treatment or non-compliant than patients
with chronic ENL (OR  0.1, 95% CI  0.001–0.05, P 
0.002). Those with chronic ENL were 3.2 times more likely to
develop moderate to severe ENL than those with acute ENL
(95% CI 1.0–10.8, P 0.047) and 8.2 times more likely to
develop any type of ENL than those with acute ENL (95% CI
 0.8–85.5, P  0.042).
Analysis of the severity during first six months of MB-MDT
showed that patients with chronic ENL were 29 times more
likely to develop any type of ENL than patients with acute
ENL (95% CI 4.3–197.2, P < 0.001). Patients with chronic
ENL were 15 times more likely to develop any type of ENL
than those with acute ENL during the second six MB-MDT
doses (95% CI  2.3–89.5, P < 0.001). The difference in
overall severity and severity related to MB-MDT intake may
be the result of most patients with acute ENL stopping treat-
ment for some time, which decreased their ENL severity com-
pared with chronic cases who were more regular with their
treatment.
DISCUSSION
This is the first study to report long-term disease patterns in
ENL and the largest reported cohort of patients (116) with
ENL from a large, well-documented patient base. It is sur-
prising that 49% of the patients with LL had an episode of
ENL. However, since the DLRC/BPRC is a referral center,
more complex cases will be referred there. We are confident
that this is a true prevalence because we reviewed informa-
tion of all cases of BL leprosy and LL. A prevalence of 50%
of LL patients having ENL in the dapsone monotherapy era
is widely cited,1 and there is a consensus that the prevalence
of ENL has decreased since the introduction of MDT. How-
ever, we could not find any published data from India on the
current prevalence of ENL in patients who were treated with
WHO-MB-MDT. There may be regional differences in the
prevalence of ENL. Becx-Bleuminck and Berhe8 reported
that only 5% of MB patients in Ethiopia treated with MDT
had ENL, and Saunderson and others11 reported a similar low
figure in an Ethiopian cohort study on MDT and reactions.
Nery and others6 found that 58% of LL patients in Brazil
were reported as having ENL. The reduction in the incidence
of ENL is attributed to the anti-inflammatory action of the
clofazimine component of MDT. Earlier diagnosis when
fewer patients have high BIs would also help reduce the in-
cidence of ENL.
Cellona and others5 compared different MDT regimens
and found that patients taking clofazimine-containing regi-
mens were less likely to experience ENL than those not tak-
ing clofazimine, with rates of ENL of 14–21% versus 24–45%,
respectively, after 12 months. Chattopadhyay and others12
compared clofazimine with ethionamide and found that pa-
tients treated with clofazimine had both fewer ENL reactions
(30% versus 50%) and superior bacterial clearance, (25.8%
versus 4.5% negativity by end of study). Clearly, not all pa-
tients are protected from ENL by clofazimine at the 50 mg/
day dosage used in MB-MDT. The difference we found be-
tween the prevalence of ENL in BL versus LL patients is
striking. We confirmed that having LL is the most important
risk factor for developing ENL. (OR  8.4, P < 0.001). Al-
though BI was not a risk factor per se, patients with BL lep-
rosy with a BI  4 are also at risk (OR 5.2, P 0.001).1,2
Since this was a retrospective study we were not able to
collect reliable data on the clinical features of ENL in our
clinic. This requires a prospective cohort study with system-
atic clinical examinations being performed on each patient.
Also, we were able to compile only a simple scale indicating
the severity of the ENL. The data on the response to treat-
ment is also limited, with the amount of steroids needed by
each patient as a surrogate marker of severity. This is another
feature that should be studied in a prospective study. This
study shows that ENL is a serious event because 92% of these
patients experienced multiple episodes of ENL over a period
of 14 months. The average age of the patients with ENL was
34.7 years, an age when they might be expected to be most
productive economically. A two-year period of chronic re-
FIGURE 7. Mean severity versus time intake by erythema nodosum leprosum (ENL) type. MB-MDT multi-drug therapy for multibacillary
leprosy. RFT  released from treatment.
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lapsing illness is likely to have severe consequences for the
patients and their families.
The separation of ENL into acute single, acute multiple,
and chronic types emphasizes how few patients experienced a
single episode of ENL, and how much more severe and pro-
longed chronic ENL is when compared with acute ENL.
These types could be used in future studies, particularly drug
trials, because patients with a chronic profile may need much
longer-term immunosuppression than patients with acute
multiple disease in which shorter immunosuppression may be
adequate. Our figures regarding episodes and drug use illus-
trate individual patient profile and may be helpful for clini-
cians in dealing with difficult ENL cases.
This study was conducted when MDT was given to MB
cases for 24 months. However, two patients had a duration of
ENL that exceeded the 24-month MDT treatment period.
Many countries are now treating MB cases for only 12
months. With a 12-month duration, 58% of our cases would
have had ENL after completing a 12-month course of MDT.
Two important considerations arise from this. First, patients
at risk for ENL will lose the protection they receive from the
clofazimine component of MB-MDT. Second, it is important
to warn patients that their ENL may continue despite their
having completed MDT. It is important to advise them to
return to the clinic with any new symptoms suggestive of ENL
because these might not be recognized as such by health
workers inexperienced in leprosy.
Most of our cases had ENL after having started MDT with
an overall mean time from diagnosis to the first episode of
ENL of 3.2 months. However, some patients had de novo
ENL and no apparent previous treatment. We also found a
strong association between compliance and the development
TABLE 4
Frequency, percentages, crude and adjusted odd ratios (ORs) comparing acute ENL versus chronic ENL at the DLRC/BPRC, Hyderabad, Andra
Pradesh, India, 1990–2000*
Variables
Acute ENL Chronic ENL 2 or
Fisher
exact P
Crude
OR 95% CI
Wald
test P
Adjusted
OR 95% CI
Likelihood
ratio test PNo. % No.
Age at diagnosis, years
< 35 12/33 36.4 33/55 60.0 1.0 1.0
 35 21/33 63.6 22/55 40.0 0.032 0.4 (0.2–0.9) 0.034 0.2 (0.04–0.7) 0.007
Ridley-Joppling classification
Borderline lepromatous 7/33 21.2 14/55 25.5 1.0
Lepromatous leprosy 26/33 78.8 41/55 74.5 0.651 0.8 (0.3–2.2) 0.649
Bacterial index at leprosy diagnosis
< 4 15/33 45.5 18/55 32.7 1.0
 4 18/33 54.5 37/55 67.3 0.233 1.7 (0.7–4.2) 0.234
Overall severity
Mild ENL 24/31 77.4 28/51 54.9 1.0 1.0
Moderate to severe ENL 7/31 22.6 23/51 45.1 0.040 2.8 (1.0–7.7) 0.037 3.2 (1.0–10.8) 0.047
Total ENL duration, months
 12 18/33 54.5 15/46 32.6 1.0 1.0
> 12 15/33 45.5 31/46 67.4 0.051 2.5 (1.0–6.2) 0.051 3.1 (0.7–3.1) 0.120
ENL/MB-MDT duration
ENL duration < 75% of MB-MDT duration 24/33 72.7 16/46 34.8 1.0 1.0
ENL duration  75% of MB-MDT duration 9/33 27.3 30/46 65.2 0.001 5.0 (1.9–13.3) 0.001 4.2 (0.7–26.1) 0.107
WHO compliance
Regular 18/31 58.1 49/53 92.5 1.0 1.0
Irregular 13/31 49.1 4/53 7.5 < 0.001 0.1 (0.03–0.4) < 0.001 0.1 (0.01–0.5) 0.002
Compliance during first 6 MB-MDT intake
Regular 19/32 59.4 46/50 92.0 1.0 1.0
Irregular 13/32 40.6 4/50 8.0 0.001 0.1 (0.04–0.4) < 0.001 0.1 (0.01–0.5) 0.002
Overall severity during MB-MDT intake
None 25/26 96.1 18/39 46.2 1.0 1.0
Some 1/26 3.9 21/39 53.8 < 0.001 29.2 (3.6–237) < 0.001 8.2 (0.8–85.5) 0.042
Severity during first 6 MB-MDT intake
None 30/32 93.8 16/49 32.6 1.0 1.0
Some 2/32 6.2 33/49 67.4 < 0.001 30.9 (6.6–146) < 0.001 29.1 (4.3–197) < 0.001
Severity during second 6 MB-MDT intake
None 24/26 92.3 16/46 34.8 1.0 1.0
Some 2/26 7.7 30/46 65.2 < 0.001 22.5 (4.7–108) < 0.001 15.1 (2.3–89.5) < 0.001
Severity during first 12 MB-MDT intake
None 25/26 96.2 15/45 33.3 1.0 1.0
Some 1/26 3.8 30/45 66.7 < 0.001 50.0 (6.2–405) < 0.001 20.8 (2.2–196) 0.001
Severity after first 12 MB-MDT intake
None 23/24 95.8 21/39 53.8 1.0 1.0
Some 1/24 4.2 18/39 46.2 < 0.001 19.7 (2.4–161) < 0.001 4.9 (0.5–46.7) 0.121
Severeity before clofazimine intake
None 3/9 33.3 4/31 12.9 1.0
Some 6/9 66.7 27/31 87.1 0.175 3.4 (0.6–19.2) 0.170
Severity during clofazimine intake
None 8/9 88.9 12/31 38.7 1.0 1.0
Some 1/9 11.1 19/31 61.3 0.010 12.7 (1.41–14) 0.024 9.8 (0.9–110) 0.037
* Severity: none No ENL, very mild ENL, or no ENL on DC; someMild, mild on prednisolone, moderate, severe, or intractable. For definitions of other abbreviations, see Table 1. Bold
P values indicate statistical significance.
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of chronic ENL. This was surprising and there are several
possible explanations. MDT kills intracellular mycobacteria,
which break up and release antigens. These antigens may
then form the focus for the formation of the immune com-
plexes that cause ENL. Regular MDT may result in continued
lyses and antigen availability. Alternatively, patients with
chronic ENL may be more compliant because they need and
seek clinical attention for their ongoing ENL. This possible
association between compliance and chronic ENL should be
explored further.
Prednisolone was used in our center as the first-line drug
for treating moderate and severe ENL. The ENL was man-
aged without prednisolone in only a few patients. The total
dosages used per patient were high. Although no overt side
effects of chronic prednisolone use were detected, there was
no routine screening for adverse effects. Long-term side ef-
fects such as hypertension, diabetes, cataract, and osteoporo-
sis could have been undetected in this cohort.
Clofazimine has been shown to be effective in treating ENL
and reducing steroid use.13 However, it takes 4–6 weeks for
the effect of clofazimine to be clinically detectable. Thus, clo-
fazimine is not useful for the management of acute ENL, but
may have role in the treatment of chronic ENL. Only 45.5%
of the patients with ENL received clofazimine. The WHO
recommends that clofazimine should be given at a dose of 300
mg/day in divided doses for no longer than 12 months.14 In
many clinics because of adverse skin and gastrointestinal ef-
fects, clofazimine is given at doses of 300 mg/day for three
months, then 200 mg/day for three months, then reduced to
100 mg/day.15 Figure 4 shows that when clofazimine was used
at a higher sustained dose of 200–300 mg/day the ENL im-
proved but only after several months of treatment at this
dose. This improvement may due to clofazimine or a natural
resolution of ENL. Some patients with chronic ENL might
have benefited from extra clofazimine at these higher doses.
However, clofazimine causes marked skin pigmentation that
is often unacceptable to our patients in Hyderabad because
their peers may recognize that they have leprosy. Short
courses of clofazimine at a dose of 100 mg/day have little
effect, especially when given early in the course of ENL. Clo-
fazimine is often only available in MDT blister packs. Thus, if
it is to be used to ameliorate ENL, loose clofazimine capsules
should also be readily obtainable.
We also observed that the last ENL episodes of some pa-
tients, especially if MB-MDT was finished, tended to be
milder than the earlier ones. This improvement with time has
implications for measuring the effectiveness of drugs used in
the treatment of ENL.
Thalidomide has been shown in four randomized con-
trolled trials and numerous case series to be very effective in
controlling acute ENL and preventing new episodes.10,16 Our
patients with acute ENL and chronic ENL might have ben-
efited from this drug. Thalidomide was prohibited in India at
the time of this study, but it is now available.
This study has highlighted the continuing problem that
ENL poses for patients and health care workers even when
MDT is routinely used. In 2004, 104,524 new cases of MB
were registered in India, of whom 10% will have a high BI
and be at risk for developing ENL.17 Our data suggest that
managing patients with prednisolone gives less than adequate
control of ENL and that clofazimine is probably not being
used optimally. Although there are guidelines suggesting in-
creased use of clofazimine in difficult cases, there are no spe-
cific guidelines on the most effective way to use clofazimine.
Further prospective clinical studies of ENL are now needed
to better define the clinical aspects of the condition and refine
response to treatment. Operational studies should be under-
taken to optimize the guidelines, defining when and how to
use clofazimine and how to monitor its effect.
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